<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prognostic value of European LeukemiaNet classification in acute myeloid leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prognostic value of European LeukemiaNet classification in acute myeloid leukemia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Prognostic value of European LeukemiaNet classification in acute myeloid leukemia</div><div class="cntnt"><table cellspacing="0"><colgroup width="15%"></colgroup><colgroup width="40%"></colgroup><colgroup span="3" width="15%"></colgroup> <tbody> <tr> <td class="subtitle1">Genetic group</td> <td class="subtitle1">Subsets</td> <td class="subtitle1">CR (%)</td> <td class="subtitle1">DFS (%)</td> <td class="subtitle1">OS (%)</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Favorable</td> <td>t(8;21)(q22;q22); <em>RUNX1-RUNX1T1</em></td> <td class="divider_bottom" rowspan="4"> <p>Younger adults: 96</p> Older adults: 83</td> <td class="divider_bottom" rowspan="4"> <p>Younger adults: 55</p> Older adults: 24</td> <td class="divider_bottom" rowspan="4"> <p>Younger adults: 66</p> Older adults: 33</td> </tr> <tr> <td>inv(16)(p13.1q22) or t(16;16)(p13.1;q22); <em>CBFB-MYH11</em></td> </tr> <tr> <td>Mutated <em>NPM1</em> without <em>FLT3</em>-ITD (normal karyotype)</td> </tr> <tr class="divider_bottom"> <td>Mutated <em>CEBPA</em> (normal karyotype)</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Intermediate-I*</td> <td>Mutated <em>NPM1</em> and <em>FLT3</em>-ITD (normal karyotype)</td> <td class="divider_bottom" rowspan="3"> <p>Younger adults: 76</p> Older adults: 61</td> <td class="divider_bottom" rowspan="3"> <p>Younger adults: 23</p> Older adults: 10</td> <td class="divider_bottom" rowspan="3"> <p>Younger adults: 28</p> Older adults: 11</td> </tr> <tr> <td>Wild-type <em>NPM1</em> and <em>FLT3</em>-ITD (normal karyotype)</td> </tr> <tr class="divider_bottom"> <td>Wild-type <em>NPM1</em> without <em>FLT3</em>-ITD (normal karyotype)</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Intermediate-II</td> <td>t(9;11)(p22;q23); <em>MLLT3-MLL</em></td> <td class="divider_bottom" rowspan="2"> <p>Younger adults: 79</p> Older adults: 63</td> <td class="divider_bottom" rowspan="2"> <p>Younger adults: 34</p> Older adults: 11</td> <td class="divider_bottom" rowspan="2"> <p>Younger adults: 45</p> Older adults: 16</td> </tr> <tr class="divider_bottom"> <td>Cytogenetic abnormalities not classified as favorable or adverse<sup>¶</sup></td> </tr> <tr> <td rowspan="4">Adverse</td> <td>inv(3)(q21q26.2) or t(3;3)(q21;q26.2); <em>RPN1-EVI1</em></td> <td rowspan="4"> <p>Younger adults: 50</p> Older adults: 39</td> <td rowspan="4"> <p>Younger adults: 10</p> Older adults: 6</td> <td rowspan="4"> <p>Younger adults: 12</p> Older adults: 3</td> </tr> <tr> <td>t(6;9)(p23;q34); <em>DEK-NUP214</em></td> </tr> <tr> <td>t(v;11)(v;q23); <em>MLL</em> rearranged</td> </tr> <tr> <td>–5 or del(5q); –7; abnl(17p); complex karyotype<sup>Δ</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">The European LeukemiaNet classification in AML uses cytogenetic and molecular data to identify four prognostic groups. When applied to 818 younger adults (&lt;60 years) and 732 older adults with primary AML treated within cooperative group trials, the prognostic groups had significantly different rates of CR, DFS, and OS at three years.</div><div class="graphic_footnotes">AML: acute myeloid leukemia; WHO: World Health Organization; CR: complete remission; DFS: disease-free survival; OS: overall survival.<br/>* Includes all AMLs with normal karyotype except for those included in the favorable subgroup.<br/>¶ For most abnormalities, adequate numbers have not been studied to draw firm conclusions regarding their prognostic significance.<br/>Δ Three or more chromosome abnormalities in the absence of one of the WHO designated recurring translocations or inversions, that is, t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), inv(3) or t(3;3).</div><div class="graphic_reference">Additional data from:

<ol>
<li>Mrózek K, Marcucci G, Nicolet DJ, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012; 30:4515.</li>
</ol>

This research was originally published in Blood. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453. Copyright © 2010 American Society of Hematology.</div><div id="graphicVersion">Graphic 80216 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
